289 related articles for article (PubMed ID: 36978046)
21. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
Front Immunol; 2022; 13():844736. PubMed ID: 35592314
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
Front Immunol; 2021; 12():781087. PubMed ID: 35069553
[TBL] [Abstract][Full Text] [Related]
23. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
24. ncRNA-mediated overexpression of ubiquitin-specific proteinase 13 contributes to the progression of prostate cancer via modulating AR signaling, DNA damage repair and immune infiltration.
Cui X; Yu H; Yao J; Li J; Li Z; Jiang Z
BMC Cancer; 2022 Dec; 22(1):1350. PubMed ID: 36564767
[TBL] [Abstract][Full Text] [Related]
25. NALCN is a potential biomarker and therapeutic target in human cancers.
He J; Xu J; Chang Z; Yan J; Zhang L; Qin Y
Front Genet; 2023; 14():1164707. PubMed ID: 37152978
[No Abstract] [Full Text] [Related]
26. Integrative analysis confirms TPX2 as a novel biomarker for clinical implication, tumor microenvironment, and immunotherapy response across human solid tumors.
Zhu M; Wang X; Zhang Q; Xie C; Wang T; Shen K; Zhang L; Zhou X
Aging (Albany NY); 2024 Feb; 16(3):2563-2590. PubMed ID: 38315450
[TBL] [Abstract][Full Text] [Related]
27. Systemic analysis of the DNA replication regulator origin recognition complex in lung adenocarcinomas identifies prognostic and expression significance.
Tang M; Chen J; Zeng T; Ye DM; Li YK; Zou J; Zhang YP
Cancer Med; 2023 Feb; 12(4):5035-5054. PubMed ID: 36205357
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
[TBL] [Abstract][Full Text] [Related]
29. Role of the Orc6 protein in origin recognition complex-dependent DNA binding and replication in Drosophila melanogaster.
Balasov M; Huijbregts RP; Chesnokov I
Mol Cell Biol; 2007 Apr; 27(8):3143-53. PubMed ID: 17283052
[TBL] [Abstract][Full Text] [Related]
30. Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: A pan-cancer analysis.
Xu J; Ma H; Shan B
PLoS One; 2022; 17(10):e0273163. PubMed ID: 36194583
[TBL] [Abstract][Full Text] [Related]
31. PANX1 is a potential prognostic biomarker associated with immune infiltration in pancreatic adenocarcinoma: A pan-cancer analysis.
Bao L; Sun K; Zhang X
Channels (Austin); 2021 Dec; 15(1):680-696. PubMed ID: 34796785
[TBL] [Abstract][Full Text] [Related]
32. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
33. Prognostic value of TMEM59L and its genomic and immunological characteristics in cancer.
Shi C; Zhang L; Chen D; Wei H; Qi W; Zhang P; Guo H; Sun L
Front Immunol; 2022; 13():1054157. PubMed ID: 36618425
[TBL] [Abstract][Full Text] [Related]
34. Pan-Cancer and Single-Cell Analysis Reveals CENPL as a Cancer Prognosis and Immune Infiltration-Related Biomarker.
Feng Z; Chen Y; Cai C; Tan J; Liu P; Chen Y; Shen H; Zeng S; Han Y
Front Immunol; 2022; 13():916594. PubMed ID: 35844598
[TBL] [Abstract][Full Text] [Related]
35. Utility of G protein-coupled oestrogen receptor 1 as a biomarker for pan-cancer diagnosis, prognosis and immune infiltration: a comprehensive bioinformatics analysis.
Fan YC; Wu W; Leng XF; Zhang HW
Aging (Albany NY); 2023 Nov; 15(21):12021-12067. PubMed ID: 37921845
[TBL] [Abstract][Full Text] [Related]
36. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
[TBL] [Abstract][Full Text] [Related]
37. An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.
Pan T; Wang S; Wang Z
J Cancer; 2023; 14(10):1809-1836. PubMed ID: 37476180
[No Abstract] [Full Text] [Related]
38. Orc6 is a component of the replication fork and enables efficient mismatch repair.
Lin YC; Liu D; Chakraborty A; Kadyrova LY; Song YJ; Hao Q; Mitra J; Hsu RYC; Arif MK; Adusumilli S; Liao TW; Ha T; Kadyrov FA; Prasanth KV; Prasanth SG
Proc Natl Acad Sci U S A; 2022 May; 119(22):e2121406119. PubMed ID: 35622890
[TBL] [Abstract][Full Text] [Related]
39. ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis.
Ning Y; Li Y; Wang H
Front Genet; 2023; 14():1108167. PubMed ID: 36713082
[No Abstract] [Full Text] [Related]
40. Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer.
Yu Y; Sun Y; Li Z; Li J; Tian D
BMC Bioinformatics; 2023 Feb; 24(1):44. PubMed ID: 36765282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
